Cut through the noise, find the signal: Intelligence for serious healthcare leaders
Analysis updated November 9, 2026
IOTA is structurally distinct from most CMMI mandatory models in one critical way: it sets a volume target, not a cost target. The 60-point Achievement domain — worth 60% of the total performance score — is explicitly calibrated to transplant count relative to a hospital-specific baseline trended forward by the national growth rate. This is performance-based payment tied directly to procedure volume, a design choice CMS has largely avoided since the Comprehensive Care for Joint Replacement (CJR) era. The implication is intentional: CMS has concluded that underutilization, not overutilization, is the primary market failure in kidney transplantation, and it is willing to pay $15,000 per Medicare FFS transplant to correct it.
The scoring architecture has an embedded structural risk that participants must understand immediately. The Achievement domain is a step-function, not a continuous scale. A hospital performing at 76% of its transplant target earns 10 points; one performing at 74% earns 0 points. This cliff effect at every 10-percentage-point band (75%, 85%, 95%, 105%, 115%, 120%, 125%) creates acute decision pressure around the final months of each performance year. Hospitals approaching a threshold boundary face genuine incentives to accelerate case scheduling, waitlist activation, and organ acceptance in Q4 of each PY — operationally legitimate behaviors, but ones that require pre-planned capacity to execute.
The Efficiency domain's dual-scoring methodology (achievement vs. improvement, with participants receiving whichever yields more points) is one of the more thoughtful design elements in recent CMMI rulemaking. It prevents high-volume programs with already-superior acceptance rates from being disadvantaged, while simultaneously rewarding lower-performing programs that demonstrate meaningful improvement. The PY 2 appendix examples illustrate the logic clearly: a hospital with a 50th-percentile acceptance rate earns 10 points on achievement scoring; if it also performed below its baseline rate, improvement scoring yields 0 — so achievement wins. This creates a floor, not a ceiling, for mid-tier performers.
The PY 1 upside-only structure was designed as an on-ramp, but the PY 2 final rule (effective July 1, 2026, with 95 eligible participants following the reduction from 103) introduced downside risk at a maximum of $2,000 per Medicare FFS kidney transplant for scores ≤40. The asymmetry is deliberate and notable: upside maxes at $15,000, downside caps at $2,000 — a 7.5:1 ratio. This suggests CMS prioritized behavioral change over financial accountability, using the downside as a corrective nudge rather than a punitive mechanism. For large-volume programs with high baseline rates, the more serious structural threat is the Achievement domain's transplant target calculation methodology: the target is trended by the national growth rate, meaning high-baseline hospitals face compounding difficulty as the benchmark rises with the field.
The Anti-Kickback Statute safe harbor inclusion is operationally significant and underappreciated. Participating hospitals can now legally structure transportation subsidies and out-of-pocket drug cost assistance for attributed patients — historically gray areas that have deterred innovation in pre-transplant care coordination. This flexibility should be built into program design from day one, not treated as a legal afterthought.
The payment formula for upside risk ($15,000 × (Score − 60) / 40) creates a linear scale between $0 at a score of 60 and $15,000 at a perfect 100. The worked example from the Financial Fact Sheet is illustrative: a hospital with a score of 78 earns $6,750 per Medicare FFS transplant. At a typical mid-size transplant program volume of 100 Medicare FFS transplants annually, that yields $675,000 in incremental IOTA payments in a single PY. A high-volume program performing 300 Medicare FFS transplants at the same score earns $2.025 million annually.
For downside scenarios, the math is less dramatic but still material. A score of 37 (the Financial Fact Sheet's Example B) generates a payment to CMS of $150 per Medicare FFS transplant ($2,000 × (40 − 37) / 40). A hospital doing 200 Medicare FFS transplants at that score owes CMS $30,000 — painful reputationally but financially manageable. The more catastrophic downside scenario is a score of 0: $2,000 × 40/40 = $2,000 per transplant. At 200 Medicare FFS transplants, that is $400,000 in downside exposure in a single PY.
Break-even framing: To qualify for any upside payment, a hospital must score ≥60. Given that Achievement alone is worth 60 points, a hospital that hits exactly 95% of its transplant target earns 30 Achievement points, needs at least 20 Efficiency + 10 Quality (or some equivalent combination) to reach 60. A conservative program should model a minimum investment level that secures approximately 50 Achievement points (≥105% of target), supplemented by reliable Quality performance (16–18 points) to reach the payment threshold without dependence on Efficiency volatility.
Staffing investment reality: The readiness roadmap explicitly recommends investing in transplant coordinators for post-transplant follow-ups. A realistic post-transplant coordinator FTE in a major metro market costs $80,000–$110,000 fully loaded. If that FTE supports 10 additional successful transplants per year — each generating $6,750 at a score of 78 — the incremental revenue is $67,500 against a $95,000 cost, not yet ROI-positive on staffing alone. The investment logic depends on coordinators supporting 15+ incremental transplants, or on avoiding graft failure events that suppress Quality domain scores enough to drag performance below the upside threshold.
Cash flow consideration: Payments are issued 5–9 months after PY close, with a 30-day targeted review window. For PY 1 (ending June 30, 2026), hospitals should not expect payment settlement before approximately March–April 2027. This lag requires operating the program on working capital for 12–18 months before first cash receipt — a material consideration for smaller transplant programs with tighter balance sheets.
High-volume, high-baseline programs face the hardest path. A hospital that performed 330 transplants historically (Financial Fact Sheet Example B) has a commensurately high transplant target. At 75% of target, it earns only 10 Achievement points. The model structurally disadvantages programs that were already optimized — a classic CMMI design tension. These programs need to focus their strategy on organ offer acceptance optimization and graft survival quality, since Achievement domain gains require the largest absolute volume increases.
Mid-volume programs (100–175 transplants annually) are the model's intended beneficiaries in terms of financial leverage. Their absolute target numbers are achievable through incremental operational changes — expanding living donor outreach, reducing organ offer refusal rates, improving waitlist management — without the fixed-cost infrastructure requirements of a major transplant center. A program moving from 90% to 115% of target captures an additional 20 Achievement points and potentially crosses from the neutral zone into upside payment.
Market consolidation risk is real. Mandatory model participation is DSA-based, meaning transplant programs within selected DSAs compete with each other for referred patients. IOTA's transparency requirement — public posting of waitlist criteria by end of PY 1 — combined with beneficiary freedom of choice creates conditions for active patient migration toward higher-performing centers. Over a six-year model run, this dynamic could accelerate volume concentration at top-performing programs, weakening the competitive position of marginal participants within the same DSA.
Interaction with ESRD Treatment Choices (ETC) Model: IOTA operates alongside ETC (launched 2021), which incentivizes dialysis facilities and nephrologists to refer more patients toward transplantation. The models are complementary by design — ETC expands the pipeline of transplant-ready patients; IOTA incents hospitals to absorb and transplant them. Organizations operating both models (or with nephrologist partners in ETC) have a structural coordination advantage.
Medicare Advantage interaction: The upside risk payment cap of $15,000 applies to both Medicare FFS and MA kidney transplants. MA plans should recognize that IOTA creates financial incentives for transplant hospitals to increase transplant rates in their enrolled populations, potentially increasing short-term inpatient costs while reducing long-term dialysis expenditures. MA plans with ESRD enrollees should model the net population cost trajectory and consider actively partnering with IOTA participants on care coordination infrastructure.
Transplant surgeons and physicians face a model where their clinical decision-making — particularly organ offer acceptance and waitlist patient activation — is now directly linked to institutional payment. The efficiency domain's organ offer acceptance rate ratio creates a structured financial incentive to accept organs that surgeons might otherwise decline. Programs must establish governance frameworks that separate individual clinical judgment from institutional performance pressure, or risk adverse selection complaints and OPTN compliance exposure.
Health systems with transplant programs should evaluate IOTA through a portfolio lens. For systems where the transplant program is already a high-margin service line, IOTA upside payments are additive contribution margin. For systems where transplant is a mission-driven but financially marginal service, IOTA's downside risk (beginning PY 2) adds financial fragility — particularly if transplant volume underperforms relative to the national-growth-rate-trended target. System CFOs should run PY 2–6 downside scenarios against realistic volume projections before the July 1, 2026 two-sided risk activation date.
Smaller independent transplant hospitals (programs doing 15–30 transplants annually at the IOTA eligibility floor) face the most acute risk. Their baselines are low enough that the target is achievable, but their infrastructure for living donor outreach, care coordination, and post-transplant follow-up is typically thinner than major academic centers. The learning system and CMS check-in infrastructure are specifically designed for this cohort — these programs should use those resources aggressively, particularly to benchmark against top performers in the first 12 months of PY 1 before downside risk activates.
Payer and MA plan strategists should track IOTA participant performance data as it becomes available through CMS transparency mechanisms. Programs scoring consistently above 80 — implying $7,500+ per Medicare transplant in IOTA payments — are demonstrating operational characteristics (organ acceptance, living donor development, post-transplant care coordination) that correlate with better long-term population outcomes for ESRD enrollees. Preferred network contracting with high-IOTA-scoring programs is a rational strategy for MA plans seeking to reduce downstream dialysis costs in their ESRD book of business.
IOTA contact: CMMItransplant@cms.hhs.gov | Model active July 1, 2025 – June 30, 2031 | 95 participating hospitals as of PY 2